Original Source(s)
Related Content
Extended antiviral therapy may not improve long COVID
Nirmatrelvir–ritonavir for up to 25 days failed to improve cognitive, autonomic, or exercise symptoms compared with placebo in a phase 2 trial.
September 4, 2026
-
4 min
FDA approves first therapy for Alexander disease
The antisense oligonucleotide reduces production of the abnormal protein that accumulates in supportive cells in the brain.
September 4, 2026
-
2 min
Nocturnal pain in elbow disorders may predict sleep quality
Prospective multicenter study found poorer sleep quality was associated with greater pain and functional disability across common elbow conditions.
August 31, 2026
-
3 min